53 results about "Chloride channel" patented technology

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, an N-oxide, or a salt thereof, Formula (1) and (b) at least one invertebrate pest control agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

The present invention belongs to the field of insecticides, and relates to a pest-killing and mite-killing composition, which contains an active component A and an active component B, a weight part ratio of the component A to the component B is 1:99-99:1, the active component A is selected from a compound I represented by the following structural formula, the active component B is selected from an organic phosphorus pest/mite killing agent, a nicotine type acetylcholine receptor (nAChR) agonist pest/mite killing agent, an apastia pest/mite killing agent, a proton gradient interference and oxidative phosphorylation affecting uncoupling pest/mite killing agent, a nereistoxin analog pest/mite killing agent, a Ryania receptor regulating pest/mite killing agent, a voltage-dependent sodium ion channel blocking pest/mite killing agent, an ecdysone receptor stimulating pest/mite killing agent, an amino butyric acid (GABA) gated chloride channel antagonism pest/mite killing agent, a microorganism pest/mite killing agent or other pest/mite killing agents, and the active component A has the following structure. The composition of the present invention has advantages of significant synergy, resistance delaying and the like, and can be used for prevention and control of a variety of pests. The compound I is defined in the instruction.

The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and/or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.

The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof

The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABA_A chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.

A compound containing at least two aromatic rings covalently bonded together, with each aromatic ring containing at least one oxyacetamide-based side chain, the compound being capable of forming a chloride ion channel across a lipid bilayer, and transporting chloride ion across the lipid bilayer.

The invention belongs to the technical field of tobacco gene engineering, and particularly relates to a tobacco chloride ion channel protein gene NtCLC-F and application thereof. The base sequence of the gene is as shown in SEQ ID NO.1. The tobacco chloride ion channel protein NtCLC-F is composed of 726 amino acid residues, wherein the 181st-500th amino acids are conserved chloride ion channel protein structural domains. The protein is related to the chloride ion content of plant leaves, and after the expression of the protein is reduced, the chloride ion content of the leaves is obviously increased. Preliminary research on a specific tobacco chloride ion channel NtCLC-F shows that the specific tobacco chloride ion channel NtCLC-F is highly related to the content of the tobacco chloride ions, and after the gene is silenced, the content of the tobacco chloride ions is obviously increased. Based on the characteristic, a certain application basis and reference can be provided for cultivation of a new tobacco variety with the chlorine ion content regulated and controlled.

The invention discloses an application of borneol in promoting a poorly differentiated nasopharyngeal cell to intake adriamycin through chloride channel mediation. With the human poorly differentiated nasopharyngeal cell (CNE-2Z) as a research object, the conclusions are explored from the angle of the chloride channel as follows: (1) the chloride channel can be an action target point of the borneol in promotion of adriamycin transportation across a CNE-2Z cytomembrane; (2) the borneol can activate a CNE-2Z cell chloride current, and the current has volume sensitivity; (3) the ClC-3 chloride channel plays an important role in promotion of adriamycin transportation across the CNE-2Z cytomembrane by the borneol; and (4) the anti-tumor effect of the adriamycin can be obviously improved by combination of the borneol and the adriamycin. The mechanism of the borneol in promotion of drug uptake through the cytomembrane is expected to be diluted from the angle of the chloride channel by discussing the relationship between the chloride channel and the drugs taken by the cell in different states; and a new theoretical basis is provided for the borneol in clinical application.

The invention discloses an application of fipronil and an insect growth regulator to an anti-ectoparasite animal compound external preparation. The anti-ectoparasite animal compound external preparation comprises the fipronil and the insect growth regulator, and the weight ratio of the fipronil to the insect growth regulator is (0.1-20):(0.01-15). The preparation method includes the step: uniformly mixing the fipronil, the insect growth regulator and acceptable accessories. The anti-ectoparasite animal compound external preparation can effectively block a gamma-aminobutyric acid regulation chloride ion channel of an insect central nervous system, interfere the insect central nervous system and induce over-excitation of insect nerves and muscles until death, unhatched or ametabolic larvae cannot emerge into adults and die, and more complete overall expelling and killing effects of the preparation are ensured. Moreover, the preparation can more rapidly enter bodies to generate effects, and efficacy can be rapidly achieved.

This invention relates to novel β-keto-amide derivatives that are found to be potent modulators of ion channels, and in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.

The present invention provides, inter alia, methods and pharmaceutical compositions for preventing, treating, or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma and chronic obstructive pulmonary disease.

A pesticidal composition comprises a synergistically effective amount of a chloride channel activator compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio) propanamide (I), N-(3-chloro-1-(pyridine-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl) sulfinyl)propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by pests comprises contacting the plant with the synergistic pesticidal composition.

The invention discloses an application of hesperetin, tangeretin and glycyrrhetinic acid in inhibiting chloride ion channels, wherein the chloride ion channels can be inhibited; the invention discloses the application in development of drugs for treatment of diarrhea, heart disease, lung disease, stomach disease, brain disease, mental disease, rhinitis, otology diseases and ocular diseases. The detection verification method has raw materials easy to obtain, and the detection method is simple.

The present invention relates to the composition and methods of using a combination of a serotonin₃ (5-HT₃) receptor antagonist, such as ondansetron, and a selective chloride channel modulator, such as flumazenil, for treatment of patients with drug addiction or dependence. Examples of the drugs include prescription drugs as well as illegal drugs, such as, but not limited to, alcohol, cocaine, nicotine, marijuana, benzodiazepines and opiates. Furthermore, this combination can be used for treatment of patients suffering from central nervous system (CNS) disorders such as, but not limited to, depression, emotional and mood disorders and loss of memory.

The invention relates to a ds RNA inhabiting expression of chloride channel gene of aphid and an application thereof. Particularly, the ds RNA inhabiting expression of chloride channel gene of aphid is a double-stranded RNA composed of nucleotide of sequences represented by SEQ ID No:1 and the nucleotide of reverse complementary sequences. The application is that the ds RNA is introduced into aphid so as to prevent and control aphid, reduce aphid survival rate or inhabit expression of chloride channel gene of aphid. The invention uses the method of in vitro ds RNA feeding, and adopts the RNA i technology to silence expression of chloride channel gene of sitobion avenae to produce lethal effect on sitobion avenae. According to real-time fluorescence quantitative PCR study on chloride channel gene of aphid after feeding, expression of chloride channel gene is remarkably inhabited. The invention shows that sequences of chloride channel gene of aphid can be applied to research on increasing wheat resistance to aphids through plant mediating RNA i technology.

The present invention provides methods for the modulation of vascular tone in a patient having compromised vascular tissue, which methods comprise the administration of a chloride channel blocking agent or a pharmaceutically acceptable salt thereof.

The invention discloses a method for measuring intracellular chlorine concentration or chloride channel gene CFTR expression of human endometrial stromal cells in a menstrual cycle so as to predict prognosis of endometrial deciduation related diseases of the human endometrial stromal cells. Intracellular chlorine concentration up-regulation and chlorine channel gene CFTR expression down-regulation in endometrial stromal cells in a menstrual cycle can hinder deciduation of the endometrial cells, and finally, repeated abortion/repeated implantation failure is caused. Restoration of CFTR expression and/or reduction of chloride ion concentration in endometrial stromal cells in a menstrual cycle can improve uterine decidualization and improve the outcome of recurrent abortion/recurrent implantation failure. The invention develops a new field for clinical prediction and treatment of recurrent abortion/recurrent implantation failure, and has a good application prospect.

The present invention discloses a human embryo kidney cell or cell line transfected with a GABA-gated chloride channel derived from an insect of the order of Lepidoptera, Diptera, Coleoptera, Homoptera, Acarina, Thysanaptera, Heteroptera, Hymenoptera or Isoptera and its use in a one-pot, high-throughput method for the measurement of the change in membrane potential in a cell or cell line. The method is particularly effective in measuring changes in membrane potential resulting from a compound acting on a GABA-gated chloride channel derived from a tobacco budworm.